by Philippa Shelton | Nov 7, 2022 | Welcome
PEGS 2022: Isogenica showcases plans for implementing machine learning tools Isogenica is attending PEGS Europe: Protein and Antibody Engineering Summit, 14-16th November 2022 Isogenica is delighted to announce we’re attending PEGS Europe 2022. ...
by Philippa Shelton | Nov 4, 2022 | Welcome
Isogenica VHH antibodies used in potential therapy for heart failure Our VHH antibodies have been put to the test as a potential new therapy for heart failure in an early-stage study from AstraZeneca published in Nature Communications. In a step forward for...
by Philippa Shelton | Nov 4, 2022 | Press Releases, Welcome
Isogenica and Frederick National Laboratory for Cancer Research team up to discover novel antibody therapeutics Announcing a new collaboration with the Frederick National Laboratory for Cancer Research UK-based antibody engineering experts Isogenica are proud... by Philippa Shelton | Sep 7, 2022 | VHH Resources
Advantages of using VHH antibodies for CAR engineering Since the first anti-CD19 CAR-T cell therapy was approved in 2017, there’s been an explosion of interest in using engineered immune cells to treat cancer. CAR constructs consist of an external antibody-based... by Philippa Shelton | Jul 12, 2022 | Welcome
Accelerating antibody discovery with machine learning A collaboration with the University of Nottingham and Aston University Advances in computing and data science, such as machine learning (ML) and artificial intelligence (AI), are transforming all aspects of...